ARC-02

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameARC-02
Drug Alias NameARC-02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload
Mechanisms of ActionAnti-CD79B
TargetsB-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTaiho Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesTaiho Oncology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A